{"id":"tacrolimus-and-sirolimus","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hyperlipidemia"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus binds to FK-binding protein and inhibits calcineurin, blocking T-cell receptor signaling and IL-2 production. Sirolimus binds to mTOR and inhibits cell cycle progression, synergistically reducing T-cell proliferation. Together, they provide dual immunosuppression for transplant recipients.","oneSentence":"Tacrolimus and sirolimus are immunosuppressive agents that inhibit T-cell activation and proliferation through different pathways to prevent organ rejection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:10:49.855Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in liver transplant recipients"}]},"trialDetails":[{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT06821542","phase":"PHASE3","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-04","conditions":"Chronic Graft-versus-host-disease","enrollment":9},{"nctId":"NCT07124078","phase":"PHASE2","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2026-03-31","conditions":"Chronic Graft-versus-host-disease","enrollment":60},{"nctId":"NCT03970096","phase":"PHASE2","title":"Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-11-19","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":120},{"nctId":"NCT06872333","phase":"PHASE2","title":"Allo HSCT for High Risk Hemoglobinopathies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-11-19","conditions":"Graft Failure, Sickle Cell Disease, Hemoglobinopathies","enrollment":62},{"nctId":"NCT06055608","phase":"PHASE2","title":"Advancing Transplantation Outcomes in Children","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-05-22","conditions":"Kidney Transplant","enrollment":200},{"nctId":"NCT00619528","phase":"NA","title":"HLA-Identical Sibling Renal Transplant Tolerance","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2008-01","conditions":"Immunosuppression, Kidney Transplantation, Graft Rejection","enrollment":88},{"nctId":"NCT01203722","phase":"PHASE1, PHASE2","title":"Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2010-09","conditions":"Hematologic Malignancies","enrollment":87},{"nctId":"NCT00544466","phase":"PHASE1, PHASE2","title":"Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2006-07-31","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":75},{"nctId":"NCT06552169","phase":"PHASE2","title":"REgulatory T Cell Therapy to Achieve Immunosuppression REduction","status":"RECRUITING","sponsor":"Singulera Therapeutics Inc.","startDate":"2025-06-13","conditions":"Kidney Transplantation","enrollment":34},{"nctId":"NCT02891603","phase":"PHASE1, PHASE2","title":"A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-06-08","conditions":"Graft Vs Host Disease, GVHD","enrollment":40},{"nctId":"NCT06832189","phase":"PHASE1","title":"EVR and EPO for Liver Transplant Tolerance","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-01-21","conditions":"Liver Transplant","enrollment":20},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT02081755","phase":"PHASE4","title":"Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Baylor Research Institute","startDate":"2014-03","conditions":"Carcinoma, Hepatocellular","enrollment":336},{"nctId":"NCT06084780","phase":"PHASE2","title":"Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)","status":"NOT_YET_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2026-02","conditions":"Secondary Malignant Neoplasm of Retroperitoneum, Secondary Malignant Neoplasm of Peritoneum, Pseudomyxoma Peritonei","enrollment":20},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT03605927","phase":"PHASE1","title":"CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-02-15","conditions":"Graft-versus-host-disease, GVHD, GVHD, Acute","enrollment":45},{"nctId":"NCT04542733","phase":"NA","title":"The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus and Leflunomide in Treatment of BK Virus Infection in Kidney Transplantation Recipient","status":"RECRUITING","sponsor":"King Chulalongkorn Memorial Hospital","startDate":"2021-02-10","conditions":"Kidney Transplant Infection, BK Virus Infection","enrollment":50},{"nctId":"NCT00133887","phase":"PHASE3","title":"TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2004-04","conditions":"Skin Cancer, Kidney Transplantation","enrollment":77},{"nctId":"NCT00799188","phase":"PHASE3","title":"CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2008-10","conditions":"Cardiac Transplantation, Skin Cancer","enrollment":175},{"nctId":"NCT04104438","phase":"PHASE4","title":"Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant","status":"COMPLETED","sponsor":"Fady M Kaldas, M.D., F.A.C.S.","startDate":"2021-01-15","conditions":"Asses Immunosuppression Modulation on Renal Recovery Post LT","enrollment":71},{"nctId":"NCT04177004","phase":"PHASE1","title":"Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-04-30","conditions":"Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":53},{"nctId":"NCT00160732","phase":"PHASE1, PHASE2","title":"Allogenic Islet Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2003-10","conditions":"Diabetes Mellitus, Type 1","enrollment":50},{"nctId":"NCT00706420","phase":"PHASE1","title":"Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2004-04-07","conditions":"Diabetes Mellitus","enrollment":17},{"nctId":"NCT01885689","phase":"PHASE2","title":"Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2014-02-10","conditions":"Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission","enrollment":72},{"nctId":"NCT07203664","phase":"PHASE4","title":"Use of Tacrolimus and MTOR Inhibitors With Anticipatory Therapy vs. Tacrolimus and Mycophenolic Acid With Universal Prophylaxis in Renal Recipients at High Risk of Posttransplant Cytomegalovirus.","status":"NOT_YET_RECRUITING","sponsor":"Hospital Universitario La Paz","startDate":"2025-10-30","conditions":"Evaluate the Effectiveness of CMV Prevention Strategies in Kidney Transplant Recipients","enrollment":30},{"nctId":"NCT02356159","phase":"PHASE1, PHASE2","title":"Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-09-24","conditions":"Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma","enrollment":34},{"nctId":"NCT07173114","phase":"","title":"New Approaches for Evaluating the Interchangeability of Reference Materials and Quality Controls (COMET-MPL)","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2025-09-22","conditions":"Hospitalization, All Conditions","enrollment":300},{"nctId":"NCT02790515","phase":"PHASE2","title":"Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-07-14","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma","enrollment":170},{"nctId":"NCT00812786","phase":"PHASE4","title":"Pharmacokinetics of Immunosuppressive Drugs in Heart Transplant Patients","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2007-07","conditions":"Heart Transplant","enrollment":42},{"nctId":"NCT06287944","phase":"PHASE1","title":"225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-07-01","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":15},{"nctId":"NCT04989686","phase":"","title":"Microsampling Assays for Immunosuppressive Drugs in Children","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2023-06-08","conditions":"Immunosuppression","enrollment":66},{"nctId":"NCT07033858","phase":"NA","title":"Evaluaion the Short Term Effects of Advograf Plus Rapamiune After Kidney Transplantation","status":"RECRUITING","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2025-03-01","conditions":"Kidney Transplant; Complications","enrollment":50},{"nctId":"NCT00544115","phase":"PHASE2","title":"Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2001-10-16","conditions":"Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia","enrollment":260},{"nctId":"NCT02711202","phase":"NA","title":"Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation","status":"COMPLETED","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2007-01","conditions":"Kidney Transplantation","enrollment":20},{"nctId":"NCT06280950","phase":"PHASE2","title":"Expanding Liver Transplant Immunosuppression Minimization Via Everolimus","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-09-12","conditions":"Liver Transplant","enrollment":340},{"nctId":"NCT02766465","phase":"PHASE2","title":"Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-03-16","conditions":"Sickle Cell Disease","enrollment":138},{"nctId":"NCT05613010","phase":"NA","title":"Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-03-19","conditions":"Transplant;Failure,Kidney, Transplant; Failure, Liver, Adherence, Medication","enrollment":65},{"nctId":"NCT02711826","phase":"PHASE1, PHASE2","title":"Treg Therapy in Subclinical Inflammation in Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-09-20","conditions":"Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant","enrollment":32},{"nctId":"NCT01163357","phase":"PHASE1","title":"Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2011-01-28","conditions":"Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia","enrollment":18},{"nctId":"NCT04339101","phase":"PHASE2","title":"Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-11-11","conditions":"Acute Leukemia, Hematologic and Lymphocytic Disorder, Myelodysplastic Syndrome","enrollment":59},{"nctId":"NCT02584647","phase":"PHASE1, PHASE2","title":"PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors","status":"TERMINATED","sponsor":"Gulam Manji","startDate":"2015-11-04","conditions":"Sarcoma, Malignant Peripheral Nerve Sheath Tumors","enrollment":39},{"nctId":"NCT00866684","phase":"PHASE4","title":"Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol","status":"TERMINATED","sponsor":"Charite University, Berlin, Germany","startDate":"2007-01-01","conditions":"Skin Cancer","enrollment":44},{"nctId":"NCT05298358","phase":"PHASE1","title":"RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2022-11-18","conditions":"Systemic Sclerosis","enrollment":1},{"nctId":"NCT03577431","phase":"PHASE1, PHASE2","title":"Liver Transplantation With Tregs at MGH","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-03-29","conditions":"Liver Transplant","enrollment":9},{"nctId":"NCT01363752","phase":"PHASE4","title":"A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-03-08","conditions":"Kidney Transplantation","enrollment":853},{"nctId":"NCT03413722","phase":"","title":"Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2018-02-01","conditions":"End Stage Renal Disease","enrollment":30},{"nctId":"NCT00679042","phase":"PHASE3","title":"Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol","status":"ACTIVE_NOT_RECRUITING","sponsor":"CellTrans Inc.","startDate":"2007-09-05","conditions":"Type 1 Diabetes Mellitus","enrollment":21},{"nctId":"NCT06584773","phase":"PHASE4","title":"Efficacy of a Quadruple Immunosuppressor Regimen With mTOR Inhibitors in Sensitized Kidney Transplant Patients","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2015-06","conditions":"Disorder Related to Renal Transplantation","enrollment":80},{"nctId":"NCT03225417","phase":"PHASE1, PHASE2","title":"Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2017-05-16","conditions":"Hematopoietic Stem Cell Transplantation, Multiple Myeloma","enrollment":142},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT03955172","phase":"NA","title":"Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2020-12-03","conditions":"Kidney Transplant Failure and Rejection","enrollment":20},{"nctId":"NCT02061800","phase":"PHASE1, PHASE2","title":"CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diane George","startDate":"2013-06-03","conditions":"Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS)","enrollment":14},{"nctId":"NCT01038505","phase":"PHASE4","title":"Comparison of Tacrolimus and Myfortic Versus Tacrolimus and Sirolimus","status":"WITHDRAWN","sponsor":"University of Miami","startDate":"2010-01","conditions":"Living Donor Kidney Transplants Patients","enrollment":""},{"nctId":"NCT01428973","phase":"PHASE2","title":"Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Liege","startDate":"2011-09","conditions":"Graft-Versus-Host Disease, Hematological Malignancies","enrollment":200},{"nctId":"NCT03654040","phase":"PHASE1, PHASE2","title":"Liver Transplantation With Tregs at UCSF","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-22","conditions":"Liver Transplant","enrollment":42},{"nctId":"NCT06338306","phase":"","title":"Tacrolimus and Personalized Therapy to Prevent Acute Rejection Episodes","status":"RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2022-01-07","conditions":"Heart Transplant Failure","enrollment":25},{"nctId":"NCT06225206","phase":"","title":"Analysis of Donor-derived Cell Free DNA in Liver Transplant Patients","status":"UNKNOWN","sponsor":"Methodist Health System","startDate":"2021-07-01","conditions":"Liver Transplant Failure","enrollment":300},{"nctId":"NCT04936971","phase":"PHASE4","title":"Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response","status":"WITHDRAWN","sponsor":"Edoardo Melilli","startDate":"2021-09","conditions":"Kidney Transplantation, Cytomegalovirus Infections","enrollment":""},{"nctId":"NCT00577278","phase":"PHASE2","title":"A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2007-10-03","conditions":"Graft Versus Host Disease, Leukemia, Lymphoma","enrollment":41},{"nctId":"NCT06196996","phase":"NA","title":"Allogeneic Regenerative Islet Transplantation for the Treatment of Brittle Type 1 Diabetes Mellitus","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2021-09-14","conditions":"Brittle Type 1 Diabetes Mellitus","enrollment":18},{"nctId":"NCT02917096","phase":"PHASE1","title":"Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2016-11-13","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":18},{"nctId":"NCT00195429","phase":"PHASE4","title":"A Study Comparing the Withdrawal of Steroids or Tacrolimus in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-08","conditions":"Kidney Failure, Graft vs Host Disease","enrollment":47},{"nctId":"NCT00519116","phase":"PHASE4","title":"Study Comparing Standard Dose and Reduced Dose Tacrolimus With Sirolimus in Renal Transplant Patients","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2000-10","conditions":"Kidney Transplantation","enrollment":150},{"nctId":"NCT03871361","phase":"PHASE2","title":"Abatacept in Patients With Birdshot HLA A29 Uveitis","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2019-04-01","conditions":"Eye Diseases, Uveitis","enrollment":15},{"nctId":"NCT03386539","phase":"PHASE3","title":"Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score","status":"UNKNOWN","sponsor":"Boston Children's Hospital","startDate":"2018-01-29","conditions":"Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases","enrollment":211},{"nctId":"NCT00681213","phase":"PHASE4","title":"Tacrolimus/Sirolimus Versus Tacrolimus/Mycophenolate Mofetil (MMF) Versus Neoral/Sirolimus in Adult, Primary Kidney Transplantation","status":"COMPLETED","sponsor":"University of Miami","startDate":"2000-05","conditions":"Adult Primary Kidney Transplantation","enrollment":150},{"nctId":"NCT00556933","phase":"PHASE4","title":"Improved Induction and Maintenance Immunosuppression in Kidney Transplantation","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2004-04-01","conditions":"End-stage Renal Disease","enrollment":180},{"nctId":"NCT00896012","phase":"PHASE4","title":"Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2008-01","conditions":"Kidney Transplantation","enrollment":58},{"nctId":"NCT01650545","phase":"PHASE1, PHASE2","title":"Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2012-07","conditions":"Disorder Related to Lung Transplantation, Bronchiolitis Obliterans, Decreased Immunologic Activity","enrollment":21},{"nctId":"NCT03797196","phase":"PHASE4","title":"RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2019-07-29","conditions":"Renal Transplant Recipients, Elderly Patients, Immunosuppression","enrollment":374},{"nctId":"NCT04415476","phase":"PHASE2","title":"Standard Therapy Using Tacrolimus, Mycophenolate Mofetil and Prednisone For Chronic Lung Transplant Rejection (BOS)","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2020-06-30","conditions":"Disorder Related to Lung Transplantation, Chronic Rejection of Lung Transplant, Decreased Immunologic Activity","enrollment":""},{"nctId":"NCT01027000","phase":"PHASE2","title":"Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-02","conditions":"Leukemia, Lymphoma","enrollment":68},{"nctId":"NCT03468478","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation","status":"COMPLETED","sponsor":"Hospital do Rim e Hipertensão","startDate":"2017-06-18","conditions":"Kidney Transplant Infection","enrollment":1209},{"nctId":"NCT01709136","phase":"PHASE2, PHASE3","title":"Pharmacokinetics of Sirolimus and Tacrolimus in Liver Transplant Recipients With Tacrolimus Toxicity","status":"TERMINATED","sponsor":"University of Pittsburgh","startDate":"2005-12","conditions":"Hypertension","enrollment":3},{"nctId":"NCT00995059","phase":"PHASE1, PHASE2","title":"Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"","conditions":"Multiple Myeloma, Refractory Multiple Myeloma","enrollment":""},{"nctId":"NCT00406393","phase":"PHASE3","title":"Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2006-11","conditions":"Leukemia, Myelocytic, Acute, Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Chronic","enrollment":304},{"nctId":"NCT02909335","phase":"PHASE3","title":"De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study","status":"WITHDRAWN","sponsor":"Rennes University Hospital","startDate":"2016-11","conditions":"Liver Transplantation","enrollment":""},{"nctId":"NCT05274308","phase":"","title":"Stability of Tacrolimus, Cyclosporine A, Everolimus and Sirolimus in Whole Blood Patient Samples","status":"COMPLETED","sponsor":"Thermo Fisher Scientific Oy","startDate":"2022-02-07","conditions":"Transplantation Drugs Stability","enrollment":46},{"nctId":"NCT01935128","phase":"PHASE4","title":"Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction","status":"COMPLETED","sponsor":"University of Toledo Health Science Campus","startDate":"2013-07-03","conditions":"Renal Transplant","enrollment":55},{"nctId":"NCT02329808","phase":"","title":"Clinical Validation of a Dried Blood Spot Method for Analysis of Immunosuppressives and Antifungals in Pediatrics","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-06","conditions":"Hematologic Diseases, Oncology Problem, Kidney Diseases","enrollment":93},{"nctId":"NCT02821026","phase":"PHASE1, PHASE2","title":"Omental Islet Transplant","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2016-05","conditions":"Type 1 Diabetes","enrollment":4},{"nctId":"NCT01126333","phase":"","title":"Long-term Follow-up of Spare the Nephron (STN) Patients","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2010-06","conditions":"Kidney Transplant","enrollment":128},{"nctId":"NCT00931255","phase":"PHASE4","title":"Tacrolimus to Sirolimus Conversion for Delayed Graft Function","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2009-04","conditions":"Kidney Transplant, Delayed Graft Function","enrollment":32},{"nctId":"NCT05294822","phase":"NA","title":"Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2019-09-30","conditions":"Diabetes","enrollment":20},{"nctId":"NCT01958190","phase":"PHASE4","title":"Study Comparing in Livertransplantation Recipients With Tacrolimus Alone Versus Tacrolimus&Sirolimus","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2011-02-07","conditions":"Liver Disease","enrollment":196},{"nctId":"NCT00789308","phase":"PHASE2","title":"Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-07-11","conditions":"Diabetes Mellitus, Type I","enrollment":24},{"nctId":"NCT00140543","phase":"PHASE3","title":"European Trial of Immunosuppression in SPK Tx","status":"COMPLETED","sponsor":"EUROSPK Study Group","startDate":"2002-02","conditions":"Diabetes Mellitus, Type 1, Diabetic Nephropathy","enrollment":228},{"nctId":"NCT02588339","phase":"PHASE2","title":"Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2016-03-04","conditions":"Graft Versus Host Disease, GVHD","enrollment":42},{"nctId":"NCT02137239","phase":"PHASE2","title":"Regimen Optimization Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-12-31","conditions":"Kidney Transplantation","enrollment":58},{"nctId":"NCT04867720","phase":"PHASE4","title":"Efficacy and Safety of CertiroBell® Tablet Plus Tacrolimus in Primary Living Donor Liver Transplant Recipients","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2021-03-16","conditions":"Liver Transplant","enrollment":112},{"nctId":"NCT03582878","phase":"PHASE4","title":"Sirolimus vs Mycophenolate With Tacrolimus in Simultaneous Pancreas and Kidney Transplantation","status":"COMPLETED","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2004-01-01","conditions":"Diabetes Mellitus, Type 1","enrollment":238},{"nctId":"NCT00566813","phase":"PHASE1, PHASE2","title":"Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2004-11","conditions":"Diabetes Mellitus, Type 1","enrollment":10},{"nctId":"NCT01220856","phase":"PHASE2","title":"Reparixin in Pancreatic Islet Transplantation","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2010-07-28","conditions":"Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus","enrollment":9},{"nctId":"NCT01653847","phase":"NA","title":"Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2013-02","conditions":"End Stage Renal Failure With Renal Transplant","enrollment":88},{"nctId":"NCT02334488","phase":"PHASE3","title":"Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function","status":"COMPLETED","sponsor":"Poitiers University Hospital","startDate":"2014-12-11","conditions":"Chronic Kidney Disease","enrollment":329},{"nctId":"NCT01936519","phase":"NA","title":"Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2013-12-16","conditions":"Immunosuppression, Renal Failure","enrollment":24},{"nctId":"NCT00358657","phase":"PHASE2","title":"Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2006-05-24","conditions":"Immunodeficiency Syndrome, Severe Aplastic Anemia, Genetic Disorder","enrollment":14},{"nctId":"NCT03415750","phase":"PHASE4","title":"Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal Transplants","status":"COMPLETED","sponsor":"Edoardo Melilli","startDate":"2016-11","conditions":"Hypertrophy, Left Ventricular","enrollment":20},{"nctId":"NCT01062555","phase":"PHASE1, PHASE2","title":"Calcineurin Inhibitor Sparing After Kidney Transplantation","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2006-10-01","conditions":"CNI Side Effects","enrollment":527}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":213,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Advagraf [Astellas Pharma bv)","Rapamune"],"phase":"marketed","status":"active","brandName":"Tacrolimus and Sirolimus","genericName":"Tacrolimus and Sirolimus","companyName":"Foundation for Liver Research","companyId":"foundation-for-liver-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tacrolimus and sirolimus are immunosuppressive agents that inhibit T-cell activation and proliferation through different pathways to prevent organ rejection. Used for Prevention of organ rejection in liver transplant recipients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}